Dr Pramod Kumar Pandey, PhD in Chemistry, is a Analytical expert with 31+ years of experience in pharmaceutical development and the founder of PharmaGuru.co, a global platform for pharmaceutical training and industry insights
Reporting Results of Pharmaceutical Impurities: A Case Study
Reporting Results of Pharmaceutical Impurities: A Case Study
Image created in Bing
Reporting Results of Pharmaceutical Impurities
In addition to specification/limit, the detection limit (DL) of impurities, the quantification limit (QL) must also be considered when reporting pharmaceutical impurity results. Impurity data should be presented in a clear, structured, and accurate manner to ensure regulatory compliance and data integrity
Expert Tips
Don’t integrate the impurity peaks having a value less than DL (detection limit)
Integrate the impurity peaks having a value more than or equal to the DL (detection limit)
Impurities having a value less than or equal to QL (quantification) should not be included in the total impurities
Impurities having a value more than or equal to QL (quantification) should be included in the total impurities